Introduction {#s1}
============

About 170 million people are affected with hepatitis C virus (HCV) throughout the world and 70% of them develop chronic infection which may progress to cirrhosis and hepatocellular carcinoma [@pone.0045698-Lavanchy1]. The current recommended treatment for chronic HCV infection is a combination of pegylated interferon (PegIFN α-2a or PegIFN α-2b) plus body-weighted ribavirin (RBV) for a duration of 24 weeks or 48 weeks depending on the HCV viral genotypes. However, only about 50% genotype 1 or 4 patients treated and 80% genotype 2 or 3 patients treated could respond completely and achieve sustained virological response (SVR) [@pone.0045698-Ghany1]. Moreover, side effects from the therapy such as influenza-like symptoms, psychiatric symptoms and hematological abnormalities, could result in the dose reduction or even the premature discontinuation of the treatment [@pone.0045698-McHutchison1]. To avoid these potential adverse events in patients who do not benefit from the treatment and to reduce the cost of therapy, it is necessary to predict an individual\'s response before or at the early stage of the treatment. Several factors, viral or host, such as HCV genotypes, baseline viral load, liver fibrosis, and mutations of interferon sensitivity determining region (ISDR), have been reported to be linked to the treatment outcomes [@pone.0045698-McHutchison1]--[@pone.0045698-Shirakawa1]. However, these factors still could not fully predict the therapy response.

In 2009, three studies which were published almost at the same time reported that single nucleotide polymorphisms (SNP) near IL28B gene region were associated with the treatment effect of pegylated-interferon and ribavirin (PegIFN/RBV) in HCV-infected patients using genome-wide association study (GWAS) method [@pone.0045698-Ge1], [@pone.0045698-Tanaka1], [@pone.0045698-Suppiah1]. Thereafter, a number of studies were published on the association between SNPs near IL28B and the clearance of HCV with or without treatments in HCV infected subjects in different ethnicities and HCV genotypes [@pone.0045698-Mangia1]--[@pone.0045698-Lunge1]. The most studied two SNPs, rs12979860 and rs8099917, are located upstream to the IL28B gene [@pone.0045698-Ge1]. The CC genotype of rs12979860 or TT of rs8099917 was considered to be associated with a better treatment response. However, results were not consistent from different studies. The aim of this study was to summarize the associations between SNPs (rs12979860 and rs8099917) near IL28B gene and outcome of the combination therapy of PegIFN plus RBV in chronic HCV infected patients from public data.

Methods {#s2}
=======

Study search and selection {#s2a}
--------------------------

Studies on the associations between SNPs of rs12979860 or rs8099917 and the treatment response in HCV infected patients were retrieved from PubMed using the following strategy: ("IL28B" OR "IL-28B" OR "interleukin 28B" OR "interleukin-28B" OR "interferon lambda 3" OR "IFN lambda 3" OR "rs12979860" OR "rs8099917") AND ("Hepatitis C" OR "HCV"). No language or time restrictions were applied and database searching for the last time was November 20, 2011. Papers retrieved were reviewed by two reviewers (Jia and Ding) independently following the including and excluding criteria ([File S1](#pone.0045698.s001){ref-type="supplementary-material"}). References of retrieved publications were also screened manually to search potential articles fitted the criteria.

Research studies met the following inclusion criteria were included in the analysis. (1) chronic HCV-infected patients with detectable HCV RNA before treatment and received the combined therapy of peginterferon and ribavirin only; (2) the clear outcomes defined as sustained virological response (SVR), i.e. undetectable HCV RNA 24 weeks or 6 months after the cessation of treatment, or non-SVR, which was detectable HCV RNA at the end of follow-up or premature discontinuation of treatment because of the poor response; (3) relevant data of therapeutic effect stratified by HCV genotypes as different HCV genotypes respond differently to the therapy.

Studies were excluded if patients suffered from other complicated liver diseases such as hepatocellular carcinoma or underwent liver transplantation. If more than one articles reported overlapping subjects, the one with more detailed descriptions of baseline information and effect data was selected. When results were stratified by races or HCV genotypes in the article, each part was considered as an independent study. However, HCV genotypes were classified into two categories, G2/3 (genotype 2 or 3) and G1/4 (genotype 1, 4 and others), according to response to the combined treatment [@pone.0045698-Ghany1], [@pone.0045698-Rumi1]. When results of treatment per protocol (TPP) analysis and intention to treatment (ITT) analysis were both reported, only ITT data were extracted for the analysis.

The following information was extracted from each study using the assessment form for data collection ([File S1](#pone.0045698.s001){ref-type="supplementary-material"}): the first author, date of publication, area of the study, demographic data of subjects, HCV genotype, duration of therapy, and the effect data of each IL28B genotype.

Data analysis {#s2b}
-------------

Meta-analysis was used to summarize associations across studies between IL28B genotypes and SVR of the combined treatment. Though studies performed in Asian populations reported a strong linkage disequilibrium between rs12979860 and rs8099917 [@pone.0045698-Hayes1]--[@pone.0045698-Lin1], results from Caucasians showed a weaker linkage disequilibrium [@pone.0045698-Ge1], [@pone.0045698-Moghaddam1], [@pone.0045698-Lagging1]. Therefore, we summarized effects of two SNPs separately. For each SNP, a recessive model was applied (for rs12979860, CC vs CT+TT; and for rs8099917, TT vs TG+GG). OR (odds ratio) of each study with its 95% CI (confidence interval) was calculated and displayed in a forest plot. Heterogeneity across studies was tested by Cochran\'s *Q* statistic and quantified by *I^2^*, a transformation of *Q* that estimates the percentage of variation in effect size that is due to heterogeneity. However, the pooled ORs were summarized using random effect model (DerSimonian and Laird method) even in absence of heterogeneity, given the diversity of the study design.

If patients fail in previous interferon-based treatment or are co-infected with human immunodeficiency virus (HIV), they respond differently to the therapy compared to patients with HCV mono-infection and treatment naïve [@pone.0045698-McHutchison1]. Therefore, separate analyses were performed to reduce the potential heterogeneity. Furthermore, in treatment-naïve patients, summarized ORs stratified by races were calculated separately in G1/4 patients and G2/3 patients. Potential publication bias was assessed by Egger method and Peter method separately. All analyses were carried out in Stata software (version 10, Package sbe24_3 and sbe19_6) and a two-tailed *P* value less than 0.05 was considered as a statistical significance.

Results {#s3}
=======

Literature retrieved {#s3a}
--------------------

The process of literature selection is showed in [figure 1](#pone-0045698-g001){ref-type="fig"}. Two hundred and forty-nine articles met the keyword selection and the full texts of 77 were gone through thoroughly after initially screening titles and abstracts. Forty three of 77 were excluded according to the inclusion and exclusion criteria. [Table 1](#pone-0045698-t001){ref-type="table"} shows the detailed information of 34 articles, including 46 independent studies [@pone.0045698-Ge1], [@pone.0045698-Mangia1], [@pone.0045698-Hayes1]--[@pone.0045698-Moghaddam1], [@pone.0045698-Kurosaki1]--[@pone.0045698-Labarga1]. Since only one study was conducted in Hispanic patients [@pone.0045698-Ge1], we incorporated it into the Caucasian group. Among those studies, 30 were on patients with HCV G1/4 and the summarized SVR rate was 45.3% (3600/7944). In contrast, the SVR rate in the rest 16 studies on patients infected with HCV G2/3 was much higher (80.1%, 1831/2287), as expected.

![Flow chart summarizing the process of study selection.](pone.0045698.g001){#pone-0045698-g001}

10.1371/journal.pone.0045698.t001

###### Information of studies included in the Meta-analysis.

![](pone.0045698.t001){#pone-0045698-t001-1}

  No                                                                               Author                     Publishing date                 Region                    Race      Genotype   Treatment duration   Gender (% for male)                       Age                       SVR   Total
  ------------------------------------------------------------- -------------------------------------------- ----------------- ------------------------------------- ----------- ---------- -------------------- --------------------- --------------------------------------------- ----- -------
  **Treatment-naïve patients**                                                                                                                                                                                                                                                             
  1                                                                     Ge et al [@pone.0045698-Ge1]              Aug-09                        USA                    African       1              48W                  62.8%           50.1±6.5[a](#nt102){ref-type="table-fn"}     45     191
  2                                                                                                                                                                   Caucasian      1              48W                  62.0%                           47.5±7.2                     488    871
  3                                                                                                                                                                   Hispanic       1              48W                  61.3%                           45.3±9.2                     38     75
  4                                                                  Hayes et al [@pone.0045698-Hayes1]           Nov-10                       Japan                    Asian        1b             48W                  56.5%          58(51--65)[c](#nt104){ref-type="table-fn"}    366    812
  5                                                                Kawaoka et al [@pone.0045698-Kawaoka1]         Sep-10                       Japan                    Asian        2              24W                   N/A                               N/A                       99     130
  6                                                               Kurosaki et al [@pone.0045698-Kurosaki1]        Sep-10                       Japan                    Asian        1b             ≥24W                 50.4%                           57.1±9.9                     194    496
  7                                                                 Mangia et al [@pone.0045698-Mangia1]          Jun-10                       Italy                  Caucasian     2/3            12/24W                57.8%                           ≥40:77.6%                    201    268
  8                                                               Scherzer et al [@pone.0045698-Scherzer1]        Jan-11                      Austria                 Caucasian      3              24W                  63.9%                           36.2±9.3                     53     69
  9                                                                     Yu et al [@pone.0045698-Yu1]              Jan-11                      Taiwan                    Asian        2              24W                  54.8%                           52.8±11.1                    429    482
  10                                                             Moghaddam et al [@pone.0045698-Moghaddam1]       Mar-11                  Norway,Denmark              Caucasian      3            14--24W                59.1%                          \>40:39.5%                    226    281
  11                                                             Fattovich et al [@pone.0045698-Fattovich1]       Mar-11                       Italy                  Caucasian      1              48W                  64.5%                             46±11                      65     121
  12                                                                                                                                                                  Caucasian     2/3             24W                  55.3%                             46±11                      144    159
  13                                                                   Lin et al [@pone.0045698-Lin1]             Mar-11                      Taiwan                    Asian        1              24W                  64.4%                           51.4±11.1                    131    191
  14                                                               Bitetto et al [@pone.0045698-Bitetto1]         Apr-11                       Italy                  Caucasian    1/4/5            48W                  51.7%          47 (18--77)[c](#nt104){ref-type="table-fn"}   47     110
  15                                                                                                                                                                  Caucasian     2/3             24W                                                                               87     101
  16                                                                 Lindh et al [@pone.0045698-Lindh1]           Jun-11        Denmark, Finland, Norway and Sweden   Caucasian     2/3            12/24W                59.8%          42 (20--72)[c](#nt104){ref-type="table-fn"}   237    341
  17                                                                Mangia et al [@pone.0045698-Mangia2]          May-11                       Italy                  Caucasian      1           24/48/72W               57.7%                             50.2                       230    454
  18                                                              de Rueda et al [@pone.0045698-deRueda1]         Jun-11                       Spain                  Caucasian     1/4             48W                  58.2%                          \>40:61.9%                    198    373
  19                                                                                                                                                                  Caucasian     2/3             48W                                                                               41     50
  20                                                                Ladero et al [@pone.0045698-Ladero1]          Jun-11                       Spain                  Caucasian      1              48W                  62.7%          48 (20--74)[c](#nt104){ref-type="table-fn"}   51     110
  21                                                              Sarrazin et al [@pone.0045698-Sarrazin1]        Jul-11                      Germany                 Caucasian      1            24--72W                55.2%          43 (18--73)[c](#nt104){ref-type="table-fn"}   291    542
  22                                                               Suppiah et al [@pone.0045698-Suppiah2]         Sep-11                     Australia                Caucasian      1              48W                  62.5%                 SVR:40.9±10.8;N-SVR:45.7±9.3           389    848
  23                                                              Sandra et al [@pone.0045698-Beinhardt1]         Sep-11                      Austria                 Caucasian      1              48W                  55.0%                           46.4±12.2                    51     113
  24                                                             De Nicola et al [@pone.0045698-DeNicola1]        Sep-11                       Italy                  Caucasian      4              48W                  83.6%          46 (27--63)[c](#nt104){ref-type="table-fn"}   50     103
  25                                                                Howell et al [@pone.0045698-Howell1]          Oct-11                        USA                    African       1              48W                  53.8%                           49.0±7.0                     45     173
  26                                                                                                                                                                  Caucasian      1              48W                  60.6%                           47.2±8.5                     101    188
  27                                                               Umemura et al [@pone.0045698-Umemura1]         Jul-11                       Japan                    Asian        1              48W                  46.2%          58 (17--74)[c](#nt104){ref-type="table-fn"}   22     52
  28                                                              Scherzer et al [@pone.0045698-Scherzer2]        Nov-11                      Austria                 Caucasian     1/4          24/48/72W               64.7%                           44.4±10.8                    182    328
  **Patients with unsuccessful or unknown treatment history**                                                                                                                                                                                                                              
  29                                                               Miyaaki et al [@pone.0045698-Miyaaki1]         Nov-11                       Japan                    Asian        1b             48W                  55.2%                           56.8±9.3                     29     67
  30                                                                 Lindh et al [@pone.0045698-Lindh2]           Nov-10                      Sweden                  Caucasian      1            24--72W                60.9%             45.4[d](#nt105){ref-type="table-fn"}       63     106
  31                                                               Hayashi et al [@pone.0045698-Hayashi1]         Jun-11                       Japan                    Asian        1b             48W                  52.5%                           55.9±10.3                    138    299
  32                                                                Halfon et al [@pone.0045698-Halfon1]          Oct-11                      Israel                  Caucasian      1              48W                  70.7%                             47±12                      77     156
  33                                                                                                                                                                  Caucasian     2/3             24W                                                                               31     42
  34                                                                  Lyoo et al [@pone.0045698-Lyoo1]            Sep-11                    South Korea                 Asian        1              48W                  56.9%                           52.4±9.7                     42     65
  35                                                              Sakamoto et al [@pone.0045698-Sakamoto1]        Feb-11                       Japan                    Asian        2              24W                  49.6%          64 (20--73)[b](#nt103){ref-type="table-fn"}   98     129
  36                                                                  Sinn et al [@pone.0045698-Sinn1]            Mar-11                       Korea                    Asian        1              48W                  53.4%                           56.6±9.2                     35     55
  37                                                                                                                                                                    Asian        2              24W                                                                               52     63
  38                                                               O\'Brien et al [@pone.0045698-OBrien1]         Jul-11                        USA                   Caucasian      1              48W                  75.4%          49 (45--53)[b](#nt103){ref-type="table-fn"}   92     646
  **HIV/HCV co-infected patients**                                                                                                                                                                                                                                                         
  39                                                                Pineda et al [@pone.0045698-Pineda1]          Sep-10                       Spain                  Caucasian     1/4             48W                  84.4%          42 (38--44)[c](#nt104){ref-type="table-fn"}   33     103
  40                                                                                                                                                                  Caucasian     2/3            24/48W                                                                             44     51
  41                                                              Aparicio et al [@pone.0045698-Aparicio1]        Oct-10                       Spain                  Caucasian     1/4             N/A                  66.9%                SVR:48.4±0.7; Non-SVR:47.2±0.6          38     114
  42                                                                                                                                                                  Caucasian      3                                                                                                29     46
  43                                                                Rallón et al [@pone.0045698-Rallon2]          Apr-11                       Spain                  Caucasian     1/4            48/72W                75.0%          42 (38--45)[b](#nt103){ref-type="table-fn"}   57     135
  44                                                                                                                                                                  Caucasian     2/3            24/48W                                                                             47     60
  45                                                               Labarga et al [@pone.0045698-Labarga1]         May-11                       Spain                  Caucasian     1/4             48W                  82.3%              43[d](#nt105){ref-type="table-fn"}        12     47
  46                                                                                                                                                                  Caucasian     2/3             48W                                                                               13     15

Age were described as

mean ± standard deviation,

median (interquartile range),

median (range) and

mean age.

N/A: not available.

Treatment-naïve patients {#s3b}
------------------------

Studies on the HCV G1/4 and the HCV G2/3 treatment-naïve patients were analyzed separately both for rs12979860 and rs8099917. The summarized SVR rate was 48.5% (2984/6151) for G1/4 group and 80.6% (1517/1881) for G2/3 group.

Seventeen studies evaluated the association between response of combined therapy and SNP of rs12979860 in HCV G1/4 patients ([Figure 2](#pone-0045698-g002){ref-type="fig"}). When data from Caucasian were combined, the CC genotype showed a favorable effect compared to CT/TT (SVR: 73.1% vs 40.5%; OR 4.08, 95%CI 3.23--5.15; *P*\<0.001). The favorable effects of CC genotype were also observed in Asian (SVR: 57.8% vs 24.8%; OR 3.77, 95%CI 2.73--5.22; *P*\<0.001) and African patients (SVR: 48.0% vs 21.0%; OR 3.42, 95%CI 1.40--8.34; *P* = 0.007). The summarized OR from all studies indicated that rs12979860 CC genotype was associated with an increased possibility of SVR in the treatment-naïve patients with HCV genotype 1 or 4 infection, when they received the PegIFN/RBV treatment (OR 3.97, 95%CI 3.29--4.80, *P*\<0.001; [Figure 2](#pone-0045698-g002){ref-type="fig"}). For patients of HCV G2/3, associations could not be observed either in Caucasian (SVR: 78.5% vs 77.5%; OR 1.04, 95%CI 0.74--1.47; *P* = 0.811) or Asian patients (SVR: 78.3% vs 66.7%; OR 1.80, 95%CI 0.69--4.74; *P* = 0.231). Neither was a significant association found in the pooled estimation (OR 1.10, 95%CI 0.79--1.52, *P* = 0.572; [Figure 3](#pone-0045698-g003){ref-type="fig"}).

![Forrest plots for association between polymorphisms and response to PegIFN/RBV in treatment-naïve HCV G1/4 patients.\
A. rs12979860 (CC vs CT/TT). B. rs8099917 (TT vs TG/GG).](pone.0045698.g002){#pone-0045698-g002}

![Forrest plots for association between polymorphisms and response to PegIFN/RBV in treatment-naïve HCV G2/3 patients.\
A. rs12979860 (CC vs CT/TT). B. rs8099917 (TT vs TG/GG).](pone.0045698.g003){#pone-0045698-g003}

We next grouped studies on Caucasian patients with complete SVR data for each rs12979860 genotype ([Table 2](#pone-0045698-t002){ref-type="table"}). There was no Asian aggregation due to the limited number of studies. The SVR rates declined as the frequencies of C allele within HCV G1/4 or G2/3 group decreased. And the SVR rates were always higher in HCV G2/3 patients than in G1/4 patients for each rs12979860 genotype. For rs12979860 genotype distribution, the frequency of favorable CC genotype was higher in HCV G2/3 whereas the unfavorable CT or TT genotype was reversed ([Table 2](#pone-0045698-t002){ref-type="table"}). The pooled estimations from these Caucasian studies were similar to those from all studies. The ORs were 4.09 (95% CI 2.98--5.62; *P*\<0.001) for HCV G1/4 group and 1.03 (95% CI 0.70--1.51; *P* = 0.893) for HCV G2/3 group respectively.

10.1371/journal.pone.0045698.t002

###### SVR rates and frequency for rs12979860 genotypes in Caucasian treatment-naïve patients with complete data.

![](pone.0045698.t002){#pone-0045698-t002-2}

                                                                                                                            Reference                                                                                                          CC                  CT                  TT
  ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------
  **SVR**                                                                                                                                                                                                                                                                      
  G1/4 (51.2%)              [@pone.0045698-Ge1], [@pone.0045698-Fattovich1], [@pone.0045698-Bitetto1], [@pone.0045698-Mangia2], [@pone.0045698-Ladero1], [@pone.0045698-Sarrazin1], [@pone.0045698-Suppiah2], [@pone.0045698-Howell1]   72.7% (793/1090)    41.6% (684/1646)    34.4% (156/454)
  G2/3 (77.8%)                                    [@pone.0045698-Mangia1], [@pone.0045698-Moghaddam1], [@pone.0045698-Scherzer1], [@pone.0045698-Fattovich1], [@pone.0045698-Bitetto1], [@pone.0045698-Lindh1]                           78.3% (403/515)     78.6% (453/576)     71.9% (92/128)
  **Genotype frequency**                                                                                                                                                                                                                                                       
  G1/4                      [@pone.0045698-Ge1], [@pone.0045698-Fattovich1], [@pone.0045698-Bitetto1], [@pone.0045698-Mangia2], [@pone.0045698-Ladero1], [@pone.0045698-Sarrazin1], [@pone.0045698-Suppiah2], [@pone.0045698-Howell1]   34.2% (1090/3190)   51.6% (1646/3190)   14.2% (454/3190)
  G2/3                                            [@pone.0045698-Mangia1], [@pone.0045698-Moghaddam1], [@pone.0045698-Scherzer1], [@pone.0045698-Fattovich1], [@pone.0045698-Bitetto1], [@pone.0045698-Lindh1]                          42.2% (515/1219)    47.3% (576/1219)    10.5% (128/1219)

Similar results were observed for rs8099917 TT genotype in chronic hepatitis C patients infected with HCV genotype 1 or 4. Compared to TG/GG genotypes, individuals bearing rs8099917 TT genotype were more likely to clear virus after PegIFN/RBV treatment both in Caucasian and Asian groups (Caucasian: 56.8% vs 35.8%, OR 2.52, 95%CI 1.77--3.57, *P*\<0.001; Asian: 54.9% vs 21.3%, OR 4.21, 95%CI 3.01--5.90, *P*\<0.001; [Figure 2](#pone-0045698-g002){ref-type="fig"}). The summarized OR for all studies was 3.43 with 95% CI from 2.43 to 4.86 (*P*\<0.001, [Figure 2](#pone-0045698-g002){ref-type="fig"}). Again, no significant association was observed in patients infected with HCV genotype 2 or 3 (OR 1.10, 95%CI 0.74--1.63, *P* = 0.648; [Figure 3](#pone-0045698-g003){ref-type="fig"}).

Patients with unsuccessful or unknown treatment history {#s3c}
-------------------------------------------------------

Studies were grouped together if they contained at least one patient failed to a previous interferon-based treatment or if no information of treatment history was given. This group was to show the impact of SNPs in the complex clinical practice since treatment response was reported to be different in patients with treatment history [@pone.0045698-Ghany1]. As expected, the summarized SVR rates were slightly lower than those in treatment-naïve patients, 34.1% (476/1394) in HCV G1/4 and 77.4% (181/234) in HCV G2/3 group. However, associations between SNPs and treatment effects were similar to that in the treatment-naïve group. The positive associations were observed in HCV G1/4 group carrying rs12979860 CC (OR 3.76, 95%CI 2.67--5.28, *P*\<0.001) or rs8099917 TT genotype (OR 4.70, 95%CI 2.80--7.89, *P*\<0.001) respectively, whereas no significant associations was found in HCV G2/3 group ([Figure 4](#pone-0045698-g004){ref-type="fig"}).

![Forrest plots for association between polymorphisms and response to PegIFN/RBV in patients possibly with treatment history.\
A. rs12979860 (CC vs CT/TT). B. rs8099917 (TT vs TG/GG).](pone.0045698.g004){#pone-0045698-g004}

HCV/HIV co-infected patients {#s3d}
----------------------------

Studies conducted in HCV/HIV co-infected patients were classified into one group, without considering the treatment history due to the similar results observed in HCV mono-infected patients with and without treatment history and the limited number of studies. The pooled results indicated similar associations as those in HCV mono-infected patients. The rs12979860 CC genotype was associated with a better treatment response in HCV G1/4 patients receiving PegIFN/RBV therapy (OR 5.20, 95%CI 3.04--8.90, *P*\<0.001; [Figure 5](#pone-0045698-g005){ref-type="fig"}), but not in HCV G2/3 patients (OR 2.60, 95%CI 0.98--6.88, *P* = 0.054). However, only one study was on rs8099917, and this study showed that re8099917 TT genotype favored the positive association in patients with HCV genotype 1 or 4, but not in genotype 2 or 3 [@pone.0045698-Aparicio1].

![Forrest plot for association between rs12979860 polymorphisms and response to PegIFN/RBV in HIV co-infected patients.](pone.0045698.g005){#pone-0045698-g005}

Publication bias {#s3e}
----------------

No obvious publication bias was observed in studies using Egger\'s test and Peters\' test respectively, as shown in [table 3](#pone-0045698-t003){ref-type="table"}.

10.1371/journal.pone.0045698.t003

###### Results for publication bias test using Egger\'s test and Peters\' test.

![](pone.0045698.t003){#pone-0045698-t003-3}

  Group                                                      *P* for Egger   *P* for Peters
  --------------------------------------------------------- --------------- ----------------
  **Rs12979860**                                                            
  HCV G1/4 and treatment- naïve patient                          0.310           0.286
  HCV G2/3 and treatment- naïve patient                          0.889           0.946
  Patients with unsuccessful or unknown treatment history        0.167           0.291
  HIV/HCV co-infected patient                                    0.043           0.342
  **Rs8099917**                                                             
  HCV G1/4 and treatment- naïve patient                          0.331           0.879
  HCV G2/3 and treatment- naïve patient                          0.960           0.532
  Patients with unsuccessful or unknown treatment history        0.189           0.143

Discussion {#s4}
==========

In the present study, we collected and summarized studies on associations between SNPs near IL28B gene (rs12979860 and rs8099917) and the treatment effect of PegIFN/RBV in chronic HCV patients. Roughly, a 3-fold significant increase of possibility to clear virus (SVR) was observed for rs12979860 CC genotype or rs8099917 TT genotype in patients infected with HCV genotype 1 or 4, irrespective of race, treatment history or the status of HIV co-infection. However, no relationship was found in patients infected with HCV genotype 2 or 3. A possible interpretation is that the effect of SNPs is attenuated by a better treatment response in patients with genotype 2 or 3 HCV as several studies have reported that rs12979860 CC or rs8099917 TT genotype was associated with faster early viral elimination in patients with genotype 2 or 3 HCV [@pone.0045698-Moghaddam1], [@pone.0045698-Scherzer1], [@pone.0045698-Yu1], [@pone.0045698-Lindh1] and the rate of SVR in treatment-naïve subjects infected with genotype 2 or 3 is 80.6%, much higher than 48.5% in patients with HCV genotype 1 or 4.

Rs12979860, located about 3 kb upstream to the IL28B coding region, resides in the putative promoter or the regulatory region of IL28B gene and may affect the gene expression as predicted by a bioinformatics tool, FastSNP (<http://fastsnp.ibms.sinica.edu.tw/pages/input_SNPListAnalysis.jsp>). The C allele has been reported to be linked to higher serum levels of IL28B, IL28A and IL29 levels, which are all involved in the induction of expression of IFN-responsive genes [@pone.0045698-Langhans1]. The CC genotype has also been reported to be associated with lower levels of intrahepatic interferon-stimulated gene (ISG) expression, which is linked to better IFN-based treatment response [@pone.0045698-Urban1]. However, the exact mechanism underlying effects of the SNP on treatment response still remains to be clarified. Nonetheless, several facts are noteworthy. Frequencies of favorable CC genotype of rs12979860 vary in different races, but in the same direction as SVR rates to PegIFN/RBV treatment [@pone.0045698-Thompson1], [@pone.0045698-McCarthy1]. And the frequencies of CC genotype increase from the lowest in patients failed to treatment, to intermediate in patients with treatment-induced clearance, and then to the highest in patients with spontaneous clearance [@pone.0045698-McCarthy1], [@pone.0045698-Rauch1]. In our analysis, the SVR rate declines with the reduction of C allele (72.7% for CC, 41.6% for CT, 34.4% for TT, [Table 2](#pone-0045698-t002){ref-type="table"}) when data from the Caucasian HCV G1/4 treatment-naïve patients were combined. Rs8099917 has been reported to be in strong linkage disequilibrium with rs12979860 [@pone.0045698-Ge1], [@pone.0045698-Hayes1]--[@pone.0045698-Lagging1]. Similar associations with HCV treatment are observed and the predictive value could not be increased when determined simultaneously [@pone.0045698-Halfon1]. Therefore, rs8099917 may share similar mechanism as rs12979860 on the association with treatment response although the mechanism is still unclear and determination of the genotype of one SNP may be enough in clinical practice.

Limitations and cautions should be taken into account before making conclusions. Firstly, selection of patients could cause a bias. Several studies analyzed patients with compliance \>80% in all patients [@pone.0045698-Lin1], [@pone.0045698-Moghaddam1], [@pone.0045698-Yu1], [@pone.0045698-Lindh1], [@pone.0045698-Halfon1] or \>80% only in non-SVR patients [@pone.0045698-Ge1], [@pone.0045698-Kurosaki1], [@pone.0045698-Fattovich1]. Non-responders are more likely to discontinue therapy prematurely [@pone.0045698-McHutchison1] and the frequencies of unfavorable genotypes tend to be higher in non-responders [@pone.0045698-McCarthy1], [@pone.0045698-Rauch1]. Therefore, selection of patients according to the compliance may result in an underestimation of SNP effect on treatment response. Secondly, therapeutic effect could be influenced by multiple variables known or unknown. For example, baseline HCV RNA level has been recognized to be reversely correlated with treatment effect [@pone.0045698-Ge1]. In this analysis, we could not adjust this factor because different studies applied different criteria to define high and low levels of HCV RNA [@pone.0045698-Ge1], [@pone.0045698-Kawaoka1], [@pone.0045698-Lin1], [@pone.0045698-Bitetto1]. Therefore, the unified design should be considered in future studies to calculate the net contribution of IL28B to treatment response. Thirdly, a group of patients with unsuccessful or unknown treatment history in our review was meant to represent the actual complex clinical setting. The interpretation of results from this group should be cautious since the portions of patients with treatment history were different among different studies. However, the study carried out in patients all failed to previous treatment also supported the association concluded in our analysis [@pone.0045698-OBrien1], indicating the predictable values of SNP near the IL28B gene. Finally, several studies were excluded from our analysis due to no sufficient data to calculate the ORs stratified by races and HCV genotypes according to our criteria [@pone.0045698-McCarthy1]--[@pone.0045698-Ridruejo1]. However, the same conclusion would be derived if these studies were included, only with the values of ORs slightly altered, since these studies also favor the results we get.

In summary, our findings suggest that SNPs of IL28B are useful baseline predictors for virological response in patients infected with genotype 1 or 4 HCV when treated with PegIFN/RBV, but not in patients with genotype 2 or 3 HCV. Therefore, determination of IL28B genotype may be necessary only in HCV genotype 1 or 4 patients. For those patients infected with difficult-to-treat genotype 1 or 4 HCV and also bearing rs12979860 non-CC genotype or rs8099917 non-TT genotype, it is urgent to develop more effective therapy strategies.
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